Sierra Oncology Inc (SRRA)
Cours de l'action
Résultats financiers
Value bought
90 derniers jours
Value sold
90 derniers jours
Net insiders buying
90 derniers jours
Trades (buy and sell)
90 derniers jours
Rechercher
| Date de notification | Date de transaction | A/V Type de transaction | Initié et/ou titre |
Nb. d'actions Prix Valeur |
Nombre d'actions | Prix | Valeur | Détails |
|---|---|---|---|---|---|---|---|---|
| 2022-04-07 | 2022-04-06 | VP Vente planifiée |
Chief Reg & Tech Ops Officer Dirigeant |
6 347
-100.0%
37,25236 409 USD |
6 347 -100.0% | 37,25 | 236 409 USD | |
| 2022-04-07 | 2022-04-05 | VP Vente planifiée |
Chief Reg & Tech Ops Officer Dirigeant |
100
-100.0%
37,093 709 USD |
100 -100.0% | 37,09 | 3 709 USD | |
| 2022-04-04 | 2022-04-04 | VP Vente planifiée |
General Counsel, CCO & Sec'y Dirigeant |
2 000
-100.0%
35,1470 277 USD |
2 000 -100.0% | 35,14 | 70 277 USD | |
| 2022-03-22 | 2022-03-18 | VP Vente planifiée |
Chief Reg & Tech Ops Officer Dirigeant |
100
-100.0%
37,053 705 USD |
100 -100.0% | 37,05 | 3 705 USD | |
| 2022-03-17 | 2022-03-17 | VP Vente planifiée |
Chief Reg & Tech Ops Officer Dirigeant |
3 453
-100.0%
37,06127 954 USD |
3 453 -100.0% | 37,06 | 127 954 USD | |
| 2022-03-04 | 2022-03-04 | VP Vente planifiée |
General Counsel, CCO & Sec'y Dirigeant |
2 000
-100.0%
30,6061 196 USD |
2 000 -100.0% | 30,60 | 61 196 USD | |
| 2022-02-08 | 2022-02-07 | VP Vente planifiée |
Chief Reg & Tech Ops Officer Dirigeant |
10 000
-100.0%
32,32323 225 USD |
10 000 -100.0% | 32,32 | 323 225 USD | |
| 2022-02-04 | 2022-02-04 | VP Vente planifiée |
General Counsel, CCO & Sec'y Dirigeant |
2 000
-100.0%
29,7859 560 USD |
2 000 -100.0% | 29,78 | 59 560 USD | |
| 2022-02-02 | 2022-02-02 | A Achat |
Longitude Capital Partners III, LLC Actionnaire important |
175 000
+inf%
27,004 725 000 USD |
175 000 +inf% | 27,00 | 4 725 000 USD | |
| 2022-02-02 | 2022-02-02 | A Achat | Administrateur non-exécutif Actionnaire important |
175 000
+inf%
27,004 725 000 USD |
175 000 +inf% | 27,00 | 4 725 000 USD | |
| 2022-02-01 | 2022-01-31 | A Achat | Administrateur non-exécutif |
150 000
+12.9%
27,004 050 000 USD |
150 000 +12.9% | 27,00 | 4 050 000 USD | |
| 2022-02-01 | 2022-01-31 | A Achat | Actionnaire important |
150 000
+12.9%
27,004 050 000 USD |
150 000 +12.9% | 27,00 | 4 050 000 USD | |
| 2022-01-31 | 2022-01-31 | A Achat | Administrateur non-exécutif Actionnaire important |
800 000
+41.3%
27,0021 600 000 USD |
800 000 +41.3% | 27,00 | 21 600 000 USD | |
| 2022-01-31 | 2022-01-31 | A Achat | Actionnaire important |
800 000
+41.3%
27,0021 600 000 USD |
800 000 +41.3% | 27,00 | 21 600 000 USD | |
| 2022-01-28 | 2022-01-26 | VP Vente planifiée |
Chief Reg & Tech Ops Officer Dirigeant |
5 000
-100.0%
27,05135 250 USD |
5 000 -100.0% | 27,05 | 135 250 USD | |
| 2022-01-28 | 2022-01-26 | VP Vente planifiée |
General Counsel & Secretary Dirigeant |
2 000
-100.0%
29,0058 000 USD |
2 000 -100.0% | 29,00 | 58 000 USD | |
| 2021-11-24 | 2021-11-24 | A Achat | Administrateur non-exécutif |
7 899
+141.0%
23,09182 348 USD |
7 899 +141.0% | 23,09 | 182 348 USD | |
| 2021-11-24 | 2021-11-23 | A Achat | Administrateur non-exécutif |
5 601
+inf%
22,95128 515 USD |
5 601 +inf% | 22,95 | 128 515 USD | |
| 2021-05-20 | 2021-05-19 | A Achat |
CEO and President Administrateur exécutif |
5 000
+inf%
17,8389 150 USD |
5 000 +inf% | 17,83 | 89 150 USD | |
| 2020-08-18 | 2020-08-18 | A Achat |
Chief Development Officer Dirigeant |
3 325
+198.5%
12,2540 738 USD |
3 325 +198.5% | 12,25 | 40 738 USD | |
| 2020-08-18 | 2020-08-18 | A Achat |
Chief Development Officer Dirigeant |
5 950
+146.9%
12,2272 710 USD |
5 950 +146.9% | 12,22 | 72 710 USD | |
| 2019-08-26 | 2019-08-23 | A Achat |
Klencke Barbara Chief Development Officer Dirigeant |
108 000
+200.0%
0,4447 380 USD |
108 000 +200.0% | 0,44 | 47 380 USD | |
| 2019-08-26 | 2019-08-22 | A Achat |
Klencke Barbara Chief Development Officer Dirigeant |
54 000
+inf%
0,4524 295 USD |
54 000 +inf% | 0,45 | 24 295 USD | |
| 2019-08-26 | 2019-08-22 | A Achat |
Klencke Barbara Chief Development Officer Dirigeant |
67 000
+inf%
0,4328 964 USD |
67 000 +inf% | 0,43 | 28 964 USD | |
| 2018-12-11 | 2018-12-10 | A Achat |
Allen Andrew R Administrateur non-exécutif |
66 000
+inf%
1,64108 240 USD |
66 000 +inf% | 1,64 | 108 240 USD | |
| 2017-03-09 | 2017-03-08 | A Achat |
You Angie Chief Bus. & Strat. Officer |
30 000
+29.1%
1,4342 900 USD |
30 000 +29.1% | 1,43 | 42 900 USD | |
| 2017-02-16 | 2017-02-14 | A Achat |
Topper James N Actionnaire important |
5 925 926
+inf%
1,358 000 000 USD |
5 925 926 +inf% | 1,35 | 8 000 000 USD | |
| 2016-03-24 | 2016-03-22 | VP Vente planifiée |
Chapman Wendy SVP Clinical Operations Dirigeant |
3 000
-100.0%
7,0121 023 USD |
3 000 -100.0% | 7,01 | 21 023 USD | |
| 2016-02-24 | 2016-02-22 | VP Vente planifiée |
Chapman Wendy SVP Clinical Operations Dirigeant |
3 000
-100.0%
7,0621 180 USD |
3 000 -100.0% | 7,06 | 21 180 USD | |
| 2016-01-25 | 2016-01-22 | VP Vente planifiée |
Chapman Wendy SVP Clinical Operations Dirigeant |
5 000
-100.0%
9,3946 973 USD |
5 000 -100.0% | 9,39 | 46 973 USD | |
| 2016-01-22 | 2016-01-22 | VP Vente planifiée |
Rodigueza Wendi Chief Scientific Officer Dirigeant |
1 000
-0.6%
9,669 660 USD |
1 000 -0.6% | 9,66 | 9 660 USD | |
| 2016-01-22 | 2016-01-21 | VP Vente planifiée |
Rodigueza Wendi Chief Scientific Officer Dirigeant |
1 000
-0.6%
10,3210 323 USD |
1 000 -0.6% | 10,32 | 10 323 USD | |
| 2016-01-22 | 2016-01-20 | VP Vente planifiée |
Rodigueza Wendi Chief Scientific Officer Dirigeant |
1 000
-0.6%
9,599 590 USD |
1 000 -0.6% | 9,59 | 9 590 USD | |
| 2016-01-19 | 2016-01-15 | VP Vente planifiée |
Glover Nicholas CEO and President Administrateur exécutif |
5 000
-100.0%
10,0450 223 USD |
5 000 -100.0% | 10,04 | 50 223 USD | |
| 2016-01-14 | 2016-01-12 | VP Vente planifiée |
Lovejoy Chandra D SVP of Reg. Affairs & Quality Dirigeant |
5 562
-100.0%
11,9366 345 USD |
5 562 -100.0% | 11,93 | 66 345 USD | |
| 2016-01-14 | 2016-01-12 | VP Vente planifiée |
Lovejoy Chandra D SVP of Reg. Affairs & Quality Dirigeant |
15 411
-73.5%
11,06170 489 USD |
15 411 -73.5% | 11,06 | 170 489 USD | |
| 2015-07-21 | 2015-07-21 | A Achat |
CHA ALBERT Administrateur non-exécutif |
4 693
+0.2%
17,0079 781 USD |
4 693 +0.2% | 17,00 | 79 781 USD | |
| 2015-07-21 | 2015-07-21 | A Achat |
CHA ALBERT Administrateur non-exécutif |
215 307
+9.7%
17,003 660 219 USD |
215 307 +9.7% | 17,00 | 3 660 219 USD | |
| 2015-07-21 | 2015-07-21 | A Achat |
ORBIMED ADVISORS LLC Administrateur non-exécutif |
175 000
+9.6%
17,002 975 000 USD |
175 000 +9.6% | 17,00 | 2 975 000 USD | |
| 2015-07-21 | 2015-07-21 | A Achat |
Topper James N Administrateur non-exécutif |
220 000
+11.2%
17,003 740 000 USD |
220 000 +11.2% | 17,00 | 3 740 000 USD | |
| 2015-07-21 | 2015-07-21 | A Achat |
VIVO VENTURES VII, LLC Former 10% holder |
4 693
+0.2%
17,0079 781 USD |
4 693 +0.2% | 17,00 | 79 781 USD | |
| 2015-07-21 | 2015-07-21 | A Achat |
VIVO VENTURES VII, LLC Former 10% holder |
215 307
+9.7%
17,003 660 219 USD |
215 307 +9.7% | 17,00 | 3 660 219 USD | |
| 2015-07-21 | 2015-07-21 | A Achat |
Thompson Peter A. Administrateur non-exécutif |
175 000
+9.6%
17,002 975 000 USD |
175 000 +9.6% | 17,00 | 2 975 000 USD |